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Abstract
Background
Environmental factors play a major role on atopic dermatitis (AD) which shows a constant
rise in prevalence in western countries over the last decades. The Hygiene Hypothesis sug-
gesting an inverse relationship between incidence of infections and the increase in atopic
diseases in these countries, is one of the working hypothesis proposed to explain this trend.
Objective
This study tested the efficacy and safety of oral administration of the bacterial lysate OM-85
(Broncho-Vaxom®, Broncho-Munal®, Ommunal®, Paxoral®, Vaxoral®), in the treatment of
established AD in children.
Methods
Children aged 6 months to 7 years, with confirmed AD diagnosis, were randomized in a dou-
ble-blind, placebo-controlled trial to receive, in addition to conventional treatment with emol-
lients and topical corticosteroids, 3.5mg of the bacterial extract OM-85 or placebo daily for 9
months. The primary end-point was the difference between groups in the occurrence of new
flares (NF) during the study period, evaluated by Hazard Ratio (HR) derived from conditional
Cox proportional hazard regression models accounting for repeated events.
Results
Among the 179 randomized children, 170 were analysed, 88 in the OM-85 and 82 in the pla-
cebo group. As expected most children in both treatment groups experienced at least 1 NF
during the study period (75 (85%) patients in the OM-85 group and 72 (88%) in the placebo
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group). Patients treated with OM-85 as adjuvant therapy had significantly fewer and delayed
NFs (HR of repeated flares = 0.80; 95% confidence interval (CI): 0.67–0.96), also when
potential confounding factors, as family history of atopy and corticosteroids use, were taken
into account (HR = 0.82; 95% CI: 0.69–0.98). No major side effect was reported, with com-
parable and good tolerability for OM-85 and placebo.
Conclusions
Results show an adjuvant therapeutic effect of a well standardized bacterial lysate OM-85
on established AD.
Introduction
Current treatment of atopic dermatitis (AD) mainly relies on the local application of topical
agents, particularly corticosteroids [1]. More rarely, in severe cases, immunosuppressants such
as cyclosporin are used [2].
The Hygiene Hypothesis developed in recent years as one of the possibilities [3–5] to
explain the predisposing role of improved hygiene in the increase of atopic diseases in indus-
trialized countries has opened new therapeutic perspectives. A causal effect is suggested
between the decrease in the incidence of infections and the increase in the incidence of AD
and, more generally, of allergic diseases [5, 6]. It was tempting, therefore, to use treatments
based on the stimulation of the immune system by derivatives mimicking the effect of bacteria,
viruses or parasites as substitute for the “protective” role of infections.
In a first step, it was confirmed that one could effectively prevent experimental models of
allergy, such as the development of allergic asthma induced following immunization with oval-
bumin, by the administration of killed infectious agents such as mycobacteria [7–9], or bacte-
rial extracts [10–13] or probiotics [14]. This strategy was successfully extended to other models
of allergy such as rhinitis [15], food allergy [16] and, interestingly enough, also to experimental
autoimmune diseases, such as insulin-dependent diabetes mellitus [17], to which the hygiene
hypothesis also applies [5]. Importantly, in experimental models of both allergy and autoim-
munity, it has been shown that signaling through single different Toll like receptors (TLR),
present at the surface of different immune cells and in particular of antigen-presenting cells
(i.e., dendritic cells), fully recapitulates the protective effect of infectious agents [14]. This sug-
gests that it is not the nature of the microbial agent(s) or extract(s) that matters, but rather the
type of TLR receptor(s) that are triggered, which by definition may be common between these
agents.
Based on these experimental results, attempts have been made to apply this strategy to
human AD. For obvious reasons it was decided not to use living infectious agents, even though
this was attempted in certain autoimmune diseases, such as multiple sclerosis using a parasite,
Trichuris suis [18, 19]. In AD it was mainly the use of probiotics that prevailed. Numerous clin-
ical trials have been published with this approach after the pioneering work of the Finnish
group of Kalliomaki [20, 21]. The results were the subject of controversy because the data were
inconsistently reproduced by different groups [22]. However, our recent meta-analysis con-
cluded that probiotics had a real effect on disease prevention, observed in about 30% of
patients [23]. Importantly, these results were mainly obtained when probiotics were adminis-
tered preventively in children at risk of developing the disease due to atopic heredity. Inconsis-
tent data are presently available on the treatment with probiotics in established AD [24–27].
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The probiotic approach is interesting but questionable because of the diversity and lack of
standardization of the preparations used.
Another approach, selected in several studies, was to use killed bacteria or bacterial extracts
with, however, contrasting results [28–31].
Here we report a new clinically innovative approach using a bacterial lysate (i.e, OM-85).
The choice of this agent for our trial was based first, on promising results obtained in experi-
mental dysimmune diseases, showing that its adequate administration could recapitulate the
protective effect of infections, according to the Hygiene Hypothesis [17]. Secondly, OM-85 has
been extensively used in the clinic as co-medication in the treatment of acute airways infec-
tions with an extremely good safety profile, both in adults and very young children in different
countries [32, 33].
As described in detail below, our trial was conducted between 2003 and 2006. We are
reporting the data today because over the last few years the strategy linked to the use of bacte-
rial derivatives in allergy has regained interest, in particular because of mechanistic studies
showing that the bacterial lysate in question is endowed with protective effects linked to stimu-
lation of TLRs [14] (and our unpublished data). This pharmacological effect is novel and
timely in the context of the immune mechanisms underlying the Hygiene Hypothesis.
Methods
The study started in June 2003 and ended in June 2006. This trial was not registered at Clini-
calTrials.gov, since only in 2005 the International Committee of Medical Journal Editors
(ICMJE) began to require trial registration before the time of first patient enrolment. The clini-
cal trial has been registered in Clinical Trials.gov: https://clinicaltrials.gov/ct2/show/
NCT03047954 Registry entry: NCT03047954. The corresponding Clinical Trial Checklist is
reported as Supporting information (see S1 Checklist). For transparency, the study protocol
was reported as Supporting information (see S1 Text). The study was approved by the French
Central Ethics Committee (CCPPRB) of Paris-Necker the March 3, 2003. All parents/legal
guardians gave written informed consent prior to enrolment in the study. The study was
reported according to CONSORT recommendations [34, 35].
Study patients
Patients eligible to recruitment were outpatients children of both sexes, aged 6 months to 7
years, with confirmed diagnosis of mild to severe AD, defined by using the UK Working
Party’s Diagnostic Criteria for AD [36] and a severity defined by a SCORAD (for SCORing
Atopic Dermatitis) [37, 38] between 25 and 70 and an affected body surface area between 15%
and 70%. AD patients under systemic steroid and/or immunosuppressive or immune-stimu-
lating therapy within 1 month of study start, or having any immunodeficiency, autoimmune
or malignant disease, or those with a known allergy, previous intolerance, known hypersensi-
tivity to the trial drug or to corticoids were ineligible. Participants in another clinical trial and/
or treatment with an experimental drug within 3 months of study start were also ineligible.
Study design and randomization
The study was a prospective, randomized (1:1), double blind, placebo controlled trial of paral-
lel groups, conducted in 8 French hospital centres (that recruited over 70% of the patients)
plus 14 French private pediatrician practitioner centres. The number of patients were ran-
domly allocated to treatment groups, according to the random permuted block scheme. In
order to balance both treatment arms in relation to the allergic status of the children, SCORAD
at entry was taken into account (Block A: SCORAD< 40, Block B: SCORAD 40). The
OM-85 as adjuvant for treatment of atopic dermatitis
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generation of the random code list including the production of sealed envelopes was per-
formed in a validated environment at the clinical pharmacy department of the sponsor
company.
We assessed participants at 6 consecutive visits: enrolment visit (day 0), 4 follow-up visits at
1, 3, 6, 9 months of treatment, and 1 post-treatment visit 12 months after inclusion.
Treatment
The investigational drug supplied was OM-85, a lyophilized lysate of 21 strains from 8 com-
mon respiratory pathogenic microorganisms (i.e. Haemophilus influenzae, Streptococcus pneu-
moniae, Klebsiella ozaenae and pneumoniae, Staphylococcus aureus, Streptococcus viridans and
pyrogenes, Neisseria catarrhalis). Each capsule contained 3.5 mg of lyophilised bacterial extract
as active principle. Matched placebo capsules were used as comparative treatment. The dosage
was one capsule per day. In young children who could not swallow the whole capsule, it was
recommended to open it and pour its content into some liquid (tea, milk, juice, etc.). All chil-
dren received conventional treatment with emollient and topical corticosteroids. In order to
harmonize treatments, the following drugs were prescribed to all children:
• Dexeryl1 (emollient): one application daily during the whole study;
• Flixovate1 cream (topical corticosteroid): one application daily during 8 days followed by 1
application every 2 days during 8 days and then 1 application every 3 days during 8 days.
Flixovate1 cream was prescribed at each visit. In case of persistence of the symptoms, the
patient was withdrawn from the study. The duration of the study treatment per patient was 9
months, followed by a 3 month follow-up period without treatment. The rationale for the
choice of the treatment regimen was to mimic at best, according to the Hygiene Hypothesis,
the situation of a microbial environment delivering a chronic, relatively long term, yet safe,
stimulus to the immune system to “protect” from disease progression.
Assessments
Primary efficacy parameter. The primary efficacy parameter was the difference between
groups (OM-85 versus placebo) in the occurrence of AD new flares (NF) during the treatment
period. An AD flare was defined as: recurrence of AD lesions rated3 according to global
evaluation criteria with a minimum of 15 days from the last flare (Table 1). NFs could be
recorded in regular or intermediate visits and between visits (reported by parents to the physi-
cian during the subsequent visit).
Table 1. New flare definition.
New
Flare
Score Definition
No 0 = remission No signs of cutaneous inflammatory lesions
No 1 = close to
remission
Very slight erythema, and/or infiltration just perceptible.
No 2 = minor lesions Erythema visible but small and/or slight infiltration/papules
Yes 3 = mild lesions Erythema of mild intensity, infiltration/papules of mild intensity, pruritus,
crusted lesions.
Yes 4 = severe lesions Marked erythema and/or infiltration/papules, pruritus, crusted lesions.
Yes 5 = higly severe
lesions
Intense erythema, infiltration/papule marked with oozing/excoriation.
https://doi.org/10.1371/journal.pone.0161555.t001
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A Review Committee, in blind conditions (members did not known neither the center nor
the real patient’s number), evaluated the pertinence of the primary efficacy variable reported
by different investigators in order to reduce at the minimal level:
• non-documented NFs;
• “relapses” (if distance from preceding NF was<15 days);
• “persistent flare” (if repeated);
• false positives, defined as: NF = Intensity3 but SCORAD<25, sum of symptoms <4, pru-
ritus<3;
• false negatives, defined as NF = Intensity <3 but SCORAD >25, sum of symptoms4, pru-
ritus>3, with the help of the patient’s diary (whenever present) or by changing non docu-
mented NFs, relapses, persisting with dates very close to visit dates into documented NFs.
The Review Committee members were the study investigator coordinators (2), clinical trial
managers (2) and a center representative member (1).
Secondary efficacy parameters. Secondary efficacy parameters were the differences
between groups in (1) changes in SCORAD over the study period and (2) in the total con-
sumption of corticosteroid.
Treatment compliance. Treatment compliance was checked by means of Drug Account-
ability. The parents/legal guardians were asked to return all unused study medications, includ-
ing empty boxes blisters at each visit. The returned unused capsules were recorded in the case
report form (CRF) by the investigator. The compliance was rated as good if more than 80% of
the capsules had been taken, as moderate if equal to 70% to 80%, and as poor, if less than 70%
of the capsules had been taken.
Tolerability. Overall tolerability of the treatment was assessed at each visit by a general
physical status at the time of examination. The presence of any adverse event was registered at
each visit, including the potential relationship with the study drug.
Statistical analysis
Analysed population. An intent-to-treat analysis (ITT) was performed, i.e., all random-
ized subjects, who had taken at least one dose of the trial medication, regardless of their com-
pliance with the protocol, were included in the analysis.
Primary efficacy parameter. The efficacy of OM-85 versus placebo was tested by
means of the Hazard Ratio (HR) estimates, obtained applying conditional Cox proportional
hazard regression models accounting for multiple events (i.e., NFs). Among these models,
we used the counting process model of Andersen and Gill [39]. The time to a NF was used
as the endpoint for the multiple-failure model, with multiple observations per subject
depending on the number of events (flares) each subject experienced during the study
period. In order to account for within-subject correlation between events, the robust vari-
ance ‘sandwich’ estimator was applied [40–42]. The HRs associated with the effect of treat-
ment on repeated occurrence of flares were showed together with their 95% confidence
intervals (95% CI). HRs lower than 1 indicate a better result in the OM-85 group compared
to placebo (i.e. longer time between flares and less subjects with a high number of flares in
the OM-85 group).
A multivariable model was also fit including sex, age (less or more than 3 years), family his-
tory of atopy in first degree relatives, and total corticosteroids use as potential confounders of
the treatment effect.
OM-85 as adjuvant for treatment of atopic dermatitis
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A per-protocol analysis was also performed including children from whom data were
recovered for the four follow-up visits planned in the protocol and considering only NFs
diagnosed during these visits (thus excluding NFs diagnosed during intermediate visits and
those reported by parents, for which potential distortion may have had a role despite
randomization).
Two supplementary analyses, not initially planned in the study protocol, were performed
only for descriptive purpose. The first one compared the number of NFs in each group cumu-
lated from the end of the treatment to visit 6 (i.e. 3 months after the end of treatment) through
the Mann-Whitney test. A second not planned analysis was conducted to identify potential dif-
ferences in the treatment effect across levels of major covariates (i.e. sex, age, family history of
atopy in parents and SCORAD at entry). Differences between HR estimates in strata of a
covariate were assessed using the Q statistic [43].
Secondary efficacy parameters. Differences between groups in the SCORAD evolution
over time (from the first to the fourth follow-up visit) were assessed applying a non-parametric
analysis of variance (ANOVA) for repeated measures, adjusting for age and sex. A non-
parametric ANOVA adjusted for the same potential confounding factors was used to compare
total consumption of topical corticosteroids (Flixovate) in the two treatment groups. Non-
parametric techniques were used for both analyses as data of interest did not follow a normal
distribution.
The sample size was derived by estimating a reduction in the rate of flares of AD over the
study period of about 20% in the placebo and 45% in the treated group, i.e. a difference
between groups of 25%. The statistical significance was set for an α = 0.05 for the primary vari-
able and the power (1-β) was set to 90%. A minimum of 84 evaluable patients per treatment
group were required to show a global superiority of OM-85 over placebo assuming around
20% of drop-out rate. An exact sample size determination would require a precise estimate of
the rate, which was unavailable at the time. P<0.05 was considered as statistically significant.
Analyses were performed using SAS version 9.2 (SAS Institute) statistical software.
Results
Patients flow through the study
Nine of the 179 patients included did not perform visit 2 (30 days following randomization),
leaving an evaluable population of 170 patients (88 to OM-85 and 82 to placebo) with at least
one assessment after randomization.
Further 19 participants withdrew during the trial, leaving a sample of 151 patients evaluable
at visit 5 (270 days), i.e., the last visit during the treatment period. Ten participants withdrew
between visit 5 and visit 6 (360 days), i.e., the last study visit after 3 months without study treat-
ment (Fig 1).
Demographic characteristics, clinical parameters at entry, and follow-up
description
Between June 2003 and June 2006, 179 patients were enrolled. One hundred thirty two patients
(74%) were recruited in 8 hospitals centers (67 OM-85 and 65 placebo) and 47 (26%) patients
(26 OM-85 and 21 placebo) by 14 private practitioners.
No difference between groups was found with reference to demographic and clinical char-
acteristics at entry (S1 Table). Seventy two percent and 76% of patients were recruited in hos-
pitals centers in the OM-85 and placebo group, respectively. The median age was about 2 in
both groups, with 67% and 71% of children aged 3 years or less in OM-85 and placebo group,
OM-85 as adjuvant for treatment of atopic dermatitis
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respectively. The proportion of males was higher in the placebo (71%), compared to OM-85
group (58%) but the difference was not statistically significant. The proportion of children
with a family history of atopy was similar in the two groups (67% and 68% in OM-85 and pla-
cebo group, respectively).
Fig 1. Study flowchart.
https://doi.org/10.1371/journal.pone.0161555.g001
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Concerning AD clinical evaluation, 47% and 52% of children in the OM-85 and placebo
groups, respectively, reported more than 8 flares during the year prior to study entry, with
about half of first symptoms occurring more than 18 months before trial inclusion in both
groups. Global evaluation of AD intensity, assessed at the baseline visit, by parents was similar
in OM-85 and placebo, with 44% and 34% of parents who judged the AD of their children
important in the OM-85 and placebo group, respectively. According to the investigators
assessment, only about 25% of children had important AD symptoms in both groups (S1
Table).
Total follow-up time was similar between groups (p = 0.83). Time to the first flare was sig-
nificantly higher in the OM-85 compared to placebo group (median days: 48.5 versus 34.0,
p<0.01) (S1 Table).
Efficacy
Primary efficacy parameter. As expected from data reported for the year before inclusion,
most children in both treatment groups experienced at least 1 NF during the study period (i.e.,
75 (85%) patients in the OM-85 group and 72 (88%) in the placebo group). Overall 268 NFs of
any type (regular visit (n = 71), intermediate visit (n = 45), between visit (n = 152)) were
recorded in the OM-85 group versus 292 NFs in the placebo group (regular visit (n = 98), inter-
mediate visit (n = 32), between visit (n = 162)). Comparable results were obtained when the
mean rate of NF per patient per month (mR/patient-month) were considered, with significantly
lower values in the patients treated with OM-85 compared to placebo (mR/patient-month = 0.35,
95%CI:0.29–0.40, and mR/patient-month = 0.46, 95%CI:0.40–0.52, respectively; multivariable
ANOVA p-value = 0.012).
Table 2 presents the number of patients who experienced an event (NF) with the corre-
sponding average time to event (in days) according to event order and treatment group. Two
HRs estimates, and their 95% confidence intervals (CI), are reported: the first considered the
multiple-events model, the second considered only the time to the first event. The HR estimate
obtained from the multiple-events model for the recurrence of new events was equal to 0.80
(95% CI, 0.67–0.96) in the crude analysis and to 0.82 (95% CI, 0.69–0.98) in the multivariable
model, when family history of atopy and total corticosteroids use were considered as co-vari-
ates. The first NF occurred on average 18 days later in the OM-85 group compared to placebo,
Table 2. Repeated events (NF) description: Number of patients experiencing an event (NF), average time to event (in days) in treatment groups.
HRs estimates are reported, considering both, a multiple-events model, and the time to the first event only.
OM-85 (N = 88) PLACEBO (N = 82) Multiple Events (NFs) Model first Event (NF) Model
# of NF Number of patients who
experienced 1 to 8 events
Average
time to event
Number of patients who
experienced 1 to 8 events
Average
time to event
HRa (95% CI) HRb (95% CI) HRa (95% CI) HRb (95% CI)
1st 75 (85%) 60.6 72 (88%) 42.2 0.80 (0.67–0.96) 0.82 (0.69–0.98) 0.71 (0.51–0.98) 0.70 (0.50–0.97)
p = 0.039 p = 0.039
2 nd 61 (69%) 52.4 64 (78%) 57.3
3 rd 52 (59%) 51.8 54 (66%) 50.5
4 th 39 (44%) 53.1 38 (46%) 56.9
5 th 25 (28%) 48.3 30 (37%) 46.2 p = 0.015 p = 0.025
6 th 8 (9%) 44.5 18 (22%) 36.4
7 th 6 (7%) 37.8 11 (13%) 39.5
8 th 2 (3%) 33.5 5 (6%) 24.2
a Crude analysis.
b Adjusted for age, sex, history of atopy in parents, and total corticosteroids use.
https://doi.org/10.1371/journal.pone.0161555.t002
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and the delay was maintained over the study period for most of the subsequent events (i.e., for
the 3rd, 5th, 6th and 8th event), leading to fewer recurrent events per patients in the OM-85
group compared to placebo. The adjusted HR estimate for the first event was 0.70 (95% CI:
0.50–0.97). Results remain similar even when the potential confounding effect of previous
number of flares was taken into account (HR = 0.82, 95% CI: 0.69–0.98, p = 0.032 and
HR = 0.71 95% CI: 0.51–0.98, p = 0.040, from the multiple-events model and the first event,
respectively).
In order to verify the absence of a significant bias related to potential differences between
flare types (as described in detail in the Methods section, NFs could be diagnosed during regu-
lar or intermediate visits or reported by parents when they occurred between visits), we con-
ducted a per-protocol analysis limited to children from whom data were recovered from the
four follow-up visits planned by protocol (i.e. 70 in the placebo and 80 in OM-85 group respec-
tively), and to NFs diagnosed during these planned visits only. Results were similar to those
reported for the main analysis (even if HR estimates were not significant due to the smaller
number of patients and events considered in this analysis). Forty nine percent of patients
(N = 39) in the OM-85 group compared to 69% (N = 48) in the placebo group experienced at
least one flare diagnosed during planned by protocol visits The difference in favour of OM-85
persisted for the subsequent events leading to an HR estimate by the multiple-events model of
0.77 (95% CI: 0.55–1.07) (Table 3).
When patients were stratified into subgroups according to sex, age, and family history of
atopy, and SCORAD at entry (<40 and40) as proxy of allergic status, the OM-85 group
showed better results than the placebo group (the HRs were all below unity, even if not signifi-
cant due to the low number of subjects in each strata) (S2 Table).
No significant difference emerged between groups in the number of flares registered during
the last 3 months of follow-up without treatment (median in the OM-85 and placebo groups
equal to 74 and 67, respectively, p = 0.73; and data not shown).
Secondary efficacy parameters. The difference between the OM-85 and the placebo
group in SCORAD evolution over time was of borderline significance (p = 0.05) (Fig 2).
SCORAD was significantly lower in the OM-85 group after 6 months of treatment (p = 0.02),
whereas the difference was still present but not significant after 9 months (p = 0.08).
The total consumption of corticosteroids (Flixovate1) was similar in the OM-85 (median =
43.0 grams, range interquartile = 20.2–91.6 grams) and the placebo (median = 42.8 grams,
range interquartile = 15.7–92.4 grams) groups (p = 0.70 for non-parametric ANOVA adjusted
for age and sex, data not shown).
Table 3. Repeated events (NF) description according to per-protocol analysis: Number of patients experiencing an event (NF), average time to
event (in days) in treatment groups. HRs consider both a multiple-events model, and the time to the first event only.
Subgroup of patients followed up visit 5 (9 months of treatment)
OM-85 (N = 80) PLACEBO (N = 70) Multiple Events (NFs) Model first Event (NF) Model
# of NF Number of Patients who
experienced 1 to 4 events
Average
time to event
Number of Patients who
experienced 1 to 4 events
Average
time to event
HRa (95% CI) HRb (95% CI) HRa (95% CI) HRb (95% CI)
1 st 39 (49%) 85 48 (69%) 61 0.74 (0.53–1.03) 0.77 (0.55–1.07) 0.69 (0.46–1.06) 0.72 (0.47–1.09)
p = 0.091 p = 0.126
2 nd 21 (26%) 128 30 (43%) 153
3 rd 7 (9%) 193 15 (21%) 222 p = 0.072 p = 0.123
4 th 4 (5%) 270 3 (4%) 270
a Crude analysis.
b Adjusted for age, sex, history of atopy in parents, and total corticosteroids use.
https://doi.org/10.1371/journal.pone.0161555.t003
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Compliance and tolerability. The average global compliance over the 9-month study
period as a percentage of the theoretical consumption of 1 capsule per day was satisfactory and
not statistically different between groups: 90.3% (Standard deviation (SD) = 16.9) for OM-85
and 91.9% (SD = 16.9) for placebo (p = 0.38, Mann-Whitney).
One hundred fifty eight patients (82 OM-85 and 76 placebo) reported 1163 adverse events
(AE) of different origin, nature, severity and duration noticed during the study (S3 Table).
Among these 1163 AEs, 983 occurred during the treatment period and 180 during the follow-
up period. The mean number of AEs per patient during the treatment period was similar for
both groups, i.e., 5.7 (SD = 3.6) events for OM-85 and 5.8 (SD = 3.8) for placebo. The majority
of these AEs were related to respiratory (54.8%) and gastrointestinal disorders (15.1%), with
no significant difference between OM-85 and placebo groups. Only 5 events of the 983 that
occurred during the treatment period were reported as possibly related to OM-85 (n = 3) or
placebo (n = 2) (S3 Table).
Discussion
A favourable effect of the bacterial lysate OM-85 on established AD, in particular on the recur-
rence of new events was reported. A protection of about 20% versus placebo (standard treat-
ment only), in the occurrence of NFs was observed, in the absence of appreciable side effects.
These results were consistent when the per-protocol group of children was considered.
These results cannot be compared side by side to those obtained with probiotics because, as
mentioned above, probiotics have not been largely used in children with established AD. They
may, however, be compared to those using killed bacteria or other bacterial extracts. Studies
using killed Mycobacterium vaccae were not conclusive [28, 30, 31, 44, 45]. A first trial sug-
gested favorable results but on a limited number of cases [44]; these results were not confirmed
in a subsequent study performed by the same group conducted in younger children (2–6 years
of age) [28] and also by other groups [30, 31]. Mycobacteria vaccae was administered parenter-
ally (subcutaneously), in a limited number of injections, therefore in very different conditions
compared to our protocol that was based on the oral administration for several consecutive
months of OM-85. Modest results were published following oral administration of a bacterial
Fig 2. SCORAD evolution over time (median, q1 and q3) by group and visit: Visit 1 (baseline), visit 2 (1
month), visit3 (3 moths), visit 4 (6 months) and visit 5 (9 month). q1 = first quartile (25˚ percentile);
q3 = third quartile (75˚ percentile). ^ p for non parametric analysis of variance (ANOVA) for repeated
measures, adjusting for age and sex. * p for visit 4 = 0.02. ** p for visit 5 = 0.08.
https://doi.org/10.1371/journal.pone.0161555.g002
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lysate containing E. coli and Enterococcus faecalis for AD prevention and including only chil-
dren with allergic heredity [46]. No efficacy was observed when the child had two allergic
parents, suggesting that when heredity was “strong” the course of disease could less easily be
influenced.
Our results are the first to indicate a clinical efficacy and long-term tolerability of OM-85,
an oral bacterial extract, as adjuvant therapy in children with established AD, and for which
the significant effect persisted even after major confounders (as corticosteroids use and AD
family history) were considered. The adjuvant therapy improved the clinical outcomes of the
conventional treatment with corticosteroids of 20%, which must encourage the search for clin-
ical or biological markers to more precisely define the subgroups of responder patients.
In addition, the analysis of subgroups of patients showed the consistency of the overall
results, in the absence of significant heterogeneity across strata.
These promising results suggest a possible wider use of OM-85 in the treatment of estab-
lished AD. It is essential, of course, to provide more definite proof by performing further clini-
cal trials, favouring the recruitment of children with moderate forms of AD with familiar
history of atopy. Further work is also needed to analyse potential differences between different
bacterial lysate preparations. Our results suggest that a mixture of bacterial derivatives might
be more effective than a particulate fraction or two bacterial strains in the treatment of moder-
ate AD [46]. Last but not least, the characterization of suitable immune biomarkers to monitor
for treatment effectiveness would represent an invaluable tool to distinguish patient’s sub-
groups presenting differential response to treatment.
Furthermore, our data together with the results obtained with probiotics, which, as already
mentioned, gave rise to a meta-analysis describing a positive result for preventive treatment
[23], indicate that non-specific modulation of the immune system by bacteria antigens, both,
pathogens and commensal, contributes to reduce AD occurrence and progression, which is in
agreement with the Hygiene Hypothesis.
These therapeutic effects are complementary to the wealth of epidemiological data support-
ing the Hygiene Hypothesis [5, 47, 48]. The underlying cellular and molecular mechanisms
remain however to be defined, notably the precise nature of the bacterial components involved
in the protective effect (i.e., pathogens recognition receptors (PRR) ligands binding to com-
mon motifs shared by pathogenic and commensal bacteria). Another area of research could be
the possible interaction of these orally administered bacterial lysates with the gut microbiome,
whose diversity has been shown to correlate with AD occurrence [49–51].
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